Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227850 | 0.79 | CYP3A4 (0.34) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24092262 | 0.77 | TSHR (0.30) | — | |
| SCHEMBL22432533 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL14671505 | 0.77 | CYP3A4 (0.32) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL27328891 | 0.75 | CYP3A4 (0.32) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12653710 | 0.75 | — | — | |
| SCHEMBL25132581 | 0.75 | — | — | |
| SCHEMBL74342 | 0.72 | — | — | |
| SCHEMBL736531 | 0.71 | — | — | |
| SCHEMBL20000809 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230383204-A1 | HEAT ACTIVATED DETERGENTS, FUELS INCLUDING SUCH DETERGENTS AND METHODS OF USE | ExxonMobil Technology and Engineering Company | 2023-11-30 | — | — | US | disclosed |
| WO-2023053016-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220016082-A1 | COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS | MEI PHARMA, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20210100775-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2021-04-08 | — | — | US | disclosed |
| WO-2021012717-A1 | ANTITUMOR COMPOUND USED AS AXL INHIBITOR AND USE THEREOF | 南京华威医药科技集团有限公司 | 2021-01-28 | — | — | WO | disclosed |
| EP-3165561-B1 | RAPID CURING THIOL EPOXY RESIN WITH IMPROVED COMPRESSION STRENGTH PERFORMANCE | BOEING CO (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10570246-B2 | Rapid curing thiol epoxy resin with improved compression strength performance | THE BOEING COMPANY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10035873-B2 | Rapid curing thiol epoxy resin with improved compression strength performance | THE BOEING COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170174822-A1 | RAPID CURING THIOL EPOXY RESIN WITH IMPROVED COMPRESSION STRENGTH PERFORMANCE | THE BOEING COMPANY | 2017-06-22 | — | — | US | disclosed |
| US-9611375-B1 | Rapid curing thiol epoxy resin with improved compression strength performance | THE BOEING COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | OPRM1, OPRD1, OPRK1 | CYP3A4 297/4885CYP2D6 461/4885CYP2C19 403/4885 |
| US-20070112036-A1 | Opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | CYP3A4 922/4885CYP2D6 619/4885CYP2C19 1471/4885 |
| US-20220016082-A1 | COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS | DNMT3A, TET2, HDAC8 | CYP3A4 1876/4885CYP2D6 2464/4885CYP2C19 2343/4885 |
| US-20210100775-A1 | COMBINATION THERAPIES | DDIT3, MCL1, ERCC2 | CYP3A4 3477/4885CYP2D6 3577/4885CYP2C19 4380/4885 |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | CYP3A4 940/4885CYP2D6 320/4885CYP2C19 1159/4885 |
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | CYP3A4 1333/4885CYP2D6 216/4885CYP2C19 1532/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | CYP3A4 2109/4885CYP2D6 730/4885CYP2C19 2422/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | CYP3A4 1935/4885CYP2D6 1684/4885CYP2C19 1127/4885 |
| US-20070010558-A1 | Opioid receptor antagonists | OPRM1, OPRK1, OPRL1 | CYP3A4 769/4885CYP2D6 413/4885CYP2C19 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.